PLPatrick Lungu

Patrick Lungu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Patrick Lungu has a total of 160 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Refining research outcomes: Lessons from the setup of an endpoint review committee and radiological review in tuberculosis observational diagnostic studies

    by Leyla Larsson, Claire J. Calderwood, Edson T. Marambire, Denise Banze, Alfred Mfinanga, Etienne Leroy-Terquem, Joseph Jacob, Daisuke Yamada, Francisco Trinchan Fernandez, Patrick Lungu, et al.

    Most tuberculosis diagnostic validation studies use microbiological or combination reference standards to define tuberculosis. We convened an Endpoint Review Committee (ERC) to define outcomes in ERASE-TB, a longitudinal cohort study across three high tuberculosis-burden countries, aimed at validating novel diagnostics for early detection. Herein, we describe processes and outcomes of the ERC. ERASE-TB enrolled 2,109 household contacts of people with tuberculosis who were followed up 6-monthly up to 24 months with clinical, microbiological, and radiological assessments at each visit. Any participants with a chest X-ray suggestive of tuberculosis or a positive Xpert MTB/Rif Ultra were investigated and eligible for endpoint review. For these, the clinical presentation, radiological, and microbiological results were reviewed independently by two study clinicians; any discordant endpoint categorisations were assessed by the ERC (first individually; if discordant, during a consensus meeting). Tuberculosis outcomes relied on predefined definitions (confirmed, likely, possible, unlikely). The ERC comprised four members: a tuberculosis programme manager, clinicians, and a radiologist. Semi-structured interviews (n = 4) with ERC members explored experiences and challenges in tuberculosis classification. A total of 96 clinical summaries underwent review, 55 were agreed internally, with the majority being categorised as confirmed tuberculosis (34/55, 61.8%). Among the remaining 41, the ERC members agreed on only 14 (34.1%) classifications, with the majority being classified as confirmed tuberculosis (10/14, 71.4%). The discordant 27 were discussed at the consensus meeting; 9/27 were classified as likely tuberculosis (33.3%), and 7/27 as possible and unlikely (25.9%). Qualitative interviews highlighted the complexity of tuberculosis diagnosis, value of longitudinal measurements, and tensions between decision making for research as compared to clinical purposes. Standardized tuberculosis classification frameworks, longitudinal data, and real-time expert review can improve diagnostic accuracy and comparability across studies. Future research should integrate structured ERC processes prospectively to refine tuberculosis case definitions and ensure robust clinical and research outcomes.

  • Open Access

    Mortality among persons with tuberculosis in Zambian hospitals: A retrospective cohort study

    by Josphat Bwembya, Ramya Kumar, Victoria Musonda, Rhehab Chimzizi, Nancy Kasese-Chanda, Lameck Goma, Mushota Kabaso, Reford Mihova, Sulani Nyimbili, Vimbai Makwambeni, et al.

    Tuberculosis (TB) mortality in Zambia remains high at 86 per 100,000 populations, translating to approximately 15,000 TB-related deaths annually. We conducted a nationwide retrospective cohort study to understand predictors, time to death, and probable causes of mortality among persons on TB treatment in Zambia. We reviewed medical records for persons with TB registered in 54 purposively selected hospitals in Zambia between January and December 2019. We fitted a Cox proportional hazards model to identify predictors of mortality. Of the 13,220 records abstracted, 10,987 were analyzed after excluding records of persons who transferred in from other hospitals, those with inconsistent dates and those whose treatment outcome was not evaluated. The majority of persons with TB were men, (61.5%, n = 6,761) with a median age of 36 years (IQR: 27–46 years). Overall, 1,063 (9.7%) died before completing TB treatment (incidence rate = 16.9 deaths per 1,000 person-months). Median age at death was 40 years (IQR: 31–52). The majority of deaths (75.7%, n = 799) occurred in the first two months of TB treatment, with a median time to death of 21 days (IQR: 6–57). Independent risk factors for TB mortality included age >54 years, being treated in Eastern, Southern, Western, Muchinga and Central provinces, receiving treatment from a third-level or mission hospital, methods of diagnosis other than Xpert MTB/RIF, extrapulmonary TB (EPTB), and positive HIV status. Probable causes of death were septic shock (18.8%), TB Immune Reconstitution Inflammatory Syndrome (TB IRIS) (17.8%), end-organ damage (13.4%), pulmonary TB (11.4%), anemia (9.6%) and TB meningitis (7.8%). These results show high mortality among people undergoing TB treatment in Zambia. Interventions targeted at persons most at risk such as the elderly, those with EPTB, and those living with HIV, can help reduce TB-related mortalities in Zambia.


  • Open Access

    Genomic Analysis of Mycobacterium tuberculosis Strains Resistant to Second-Line Anti-Tuberculosis Drugs in Lusaka, Zambia

    by Joseph Yamweka Chizimu, Eddie Samuneti Solo, Precious Bwalya, Thoko Flav Kapalamula, Kaemba Kunkuta Mwale, David Squarre, Misheck Shawa, Patrick Lungu, David Atomanyi Barnes, Kaunda Yamba, et al.

    The emergence of pre-extensively drug-resistant tuberculosis (pre-XDR-TB) is a threat to TB control programs in developing countries such as Zambia. Studies in Zambia have applied molecular techniques to understand drug-resistance-associated mutations, circulating lineages and transmission patterns of multi-drug-resistant (MDR) Mycobacterium tuberculosis. However, none has reported genotypes and mutations associated with pre-XDR TB. This study characterized 63 drug-resistant M. tuberculosis strains from the University Teaching Hospital between 2018 and 2019 using targeted gene sequencing and conveniently selected 50 strains for whole genome sequencing. Sixty strains had resistance mutations associated to MDR, one polyresistant, and two rifampicin resistant. Among MDR strains, seven percent (4/60) had mutations associated with pre-XDR-TB. While four, one and nine strains had mutations associated with ethionamide, para-amino-salicylic acid and streptomycin resistances, respectively. All 50 strains belonged to lineage 4 with the predominant sub-lineage 4.3.4.2.1 (38%). Three of four pre-XDR strains belonged to sub-lineage 4.3.4.2.1. Sub-lineage 4.3.4.2.1 strains were less clustered when compared to sub-lineages L4.9.1 and L4.3.4.1 based on single nucleotide polymorphism differences. The finding that resistances to second-line drugs have emerged among MDR-TB is a threat to TB control. Hence, the study recommends a strengthened routine drug susceptibility testing for second-line TB drugs to stop the progression of pre-XDR to XDR-TB and improve patient treatment outcomes.


  • Open Access

    Impact of the COVID-19 Pandemic on Tuberculosis Testing and Treatment at a Tertiary Hospital in Zambia

    by Joelle I. Rosser, Christabel Phiri, Juliette T. Bramante, Sombo Fwoloshi, Chipepo Kankasa, Patrick Lungu, Raphael Chanda, Peter Chipimo, Lloyd Mulenga, Cassidy W. Claassen, et al.

    : Globally, tuberculosis (TB) testing and treatment have declined dramatically during the COVID-19 pandemic. We quantified the change in TB visits, testing, and treatment compared with a 12-month pre-pandemic baseline at the national referral hospital’s TB Clinic in Lusaka, Zambia, in the first year of the pandemic. We stratified the results into early and later pandemic periods. In the first 2 months of the pandemic, the mean number of monthly TB clinic visits, prescriptions, and positive TB polymerase chain reaction (PCR) tests decreased as follow: −94.1% (95% CI: −119.4 to −68.8%), −71.4% (95% CI: −80.4 to −62.4%), and −73% (95% CI: −95.5 to −51.3%), respectively. TB testing and treatment counts rebounded in the subsequent 10 months, although the number of prescriptions and TB-PCR tests performed remained significantly lower than pre-pandemic. The COVID-19 pandemic significantly disrupted TB care in Zambia, which could have long-lasting impacts on TB transmission and mortality. Future pandemic preparedness planning should incorporate strategies developed over the course of this pandemic to safeguard consistent, comprehensive TB care.


  • Open Access

    Undernotification and underreporting of tuberculosis in Zambia: a national data quality assessment

    by P. S. Lungu, M. E. Kabaso, R. Mihova, A. Silumesii, T. Chisenga, C. Kasapo, I. Mwaba, A. D. Kerkhoff, M. Muyoyeta, R. Chimzizi, et al.

    Background: Despite national implementation of several high impact interventions and innovations to bolster tuberculosis (TB) detection and improve quality of TB services in Zambia, notifications have been declining since 2004. A countrywide data quality assessment (DQA) of Zambia’s National TB and Leprosy Programme (NTLP) was undertaken to quantify the degree to which undernotification and underreporting of TB notifications may be occurring. Methods: The NTLP conducted a retrospective DQA of health facilities in high burden districts in all ten Zambian provinces. Multiple routine programmatic data sources were triangulated through a multi-step verification process to enumerate the total number of unique TB patients diagnosed between 1st January and 31st August 2019; both bacteriologically confirmed and clinically diagnosed TB patients were included. Undernotification was defined as the number of TB patients identified through the DQA that were not documented in facility treatment registers, while underreporting was defined as the number of notified TB cases not reported to the NTLP. Results: Overall, 265 health facilities across 55 districts were assessed from which 28,402 TB patients were identified; 94.5% of TB patients were ≥ 15 years old, 65.1% were male, 52.0% were HIV-positive, and 89.6% were a new/relapse case. Among all TB cases, 32.8% (95%CI: 32.2–33.3) were unnotified. Undernotification was associated with age ≥ 15 years old (adjusted prevalence odds ratio [aPOR] = 2.4 [95%CI: 2.0–2.9]), HIV-positive status (aPOR = 1.6 [95%CI: 1.5–1.8]), being a new/relapse TB case (aPOR = 17.5 [95%CI: 13.4–22.8]), being a clinically diagnosed TB case (aPOR = 4.2 [95%CI:3.8–4.6]), and being diagnosed at a hospital (range, aPOR = 1.5 [95%CI: 1.3–1.6] to 2.6 [95%CI: 2.3–2.9]). There was substantial heterogeneity in the proportion of unnotified TB cases by province (range, 18.2% to 43.6%). In a sub-analysis among 22,199 TB patients with further data available, 55.9% (95%CI: 55.2–56.6) were notified and reported to the NTLP, 32.8% (95%CI: 32.2–33.4) were unnotified, and 11.3% (95%CI: 10.9–11.7) went unreported to the NTLP. Conclusions: The findings from Zambia’s first countrywide TB programme DQA demonstrate substantial undernotification and underreporting of TB cases across all provinces. This underscores the urgent need to implement a robust and integrated data management system to facilitate timely registration and reporting of all TB patients who are diagnosed and treated.


  • Open Access

    Expression of mycobacterium tuberculosis induced SOCS3 and STAT3 and the implications on innate immunity in TB patients vs healthy contacts in high TB/HIV endemic setting: A cross-sectional analytical study

    by Patrick Lungu, Kabaso Mushota, Evarist Njelesani, Thomas Sukwa, Shabir Lakhi, Peter Mwaba

    Background: Mycobacterium tuberculosis (TB) remains a disease of global health concern and a leading cause of mortality arising from an infectious agent. Protective immunity to TB remains unclear. Suppressor of cytokine signaling-3 (SOCS3) and signal transduction and activator of transcription-3 (STAT3) genes have shown potential to influence innate immunity. We, therefore, explored the expression of SOCS3 and STAT3 and their implications on the innate immunity in TB patients and their healthy close contacts. Methods: We recruited 72 TB patients and 62 healthy contacts from a high TB and HIV endemic setting (Lusaka, Zambia). We used RT-PCRT and flow cytometry to quantify the expression of SOCS, STAT3 and cytokines respectively. Data was analysed Stata version 14.0 and figures were developed in GraphPad prism version 9.1.0 (221). Assessment for associations for categorical and continuous variables was analysed using the Chi-square test and Mann-Whitney test respectively. Spearman’s rank correlation was used to evaluate the relationship between SOCS3 and IL-6. A p-value < 0.05 was considered statistically significant. Results: Healthy contacts markedly expressed SOCS3 in both unstimulated and stimulated whole blood in comparison to TB patients (p P = < 0.0001) and IL-10 (P = p = 0.044) were markedly elevated in TB patients in comparison to healthy contacts. IL-6 and SOCS3 correlated significantly in healthy contacts only (r = 0.429, p = 0.02). Conclusions: Both SOCS3 and STAT3 are genes of importance in mounting protective innate immunity against TB. We propose that SOCS3 stimulation and inhibition of STAT3 as possible approaches in gene therapy and vaccine development for TB.


  • Open Access

    A 10-year Review of TB Notifications and Mortality Trends Using a Joint Point Analysis in Zambia - a High TB burden country

    by Patrick Lungu, Clara Kasapo, Reford Mihova, Rhehab Chimzizi, Lyapa Sikazwe, Isaac Banda, Luchenga Adam Mucheleng'ANga, Pascalina Chanda-Kapata, Nathan Kapata, Alimuddin Zumla, et al.


  • Top Cited Papers
    Open Access

    Tuberculosis, HIV/AIDS and Malaria Health Services in sub-Saharan Africa – A Situation Analysis of the Disruptions and Impact of the COVID-19 Pandemic

    by Pascalina Chanda-Kapata, Francine Ntoumi, Nathan Kapata, Patrick Lungu, Luchenga Adam Mucheleng'ANga, Jeremiah Chakaya, John Tembo, Cordelia Himwaze, Rashid Ansumana, Danny Asogun, et al.


  • Top Cited Papers
    Open Access

    The WHO Global Tuberculosis 2021 Report – not so good news and turning the tide back to End TB

    by Jeremiah Chakaya, Eskild Petersen, Rebecca Nantanda, Brenda N. Mungai, Giovanni Battista Migliori, Farhana Amanullah, Patrick Lungu, Francine Ntoumi, Nagalingeswaran Kumarasamy, Markus Maeurer, et al.


  • Open Access

    Incidental Tuberculosis in sudden, unexpected, and violent deaths in the community Lusaka, Zambia - A descriptive forensic post-mortem examination study

    by Luchenga Adam Mucheleng'ANga, Cordilia M. Himwaze, Viktor Telendiy, Suzyani Simumba, Jonathan Soko, Nathan Kayonde, Bwalya Mulenga, Amos Hamukale, Aaron Lunda Shibemba, Patrick S. Lungu, et al.